Biotech’s Iron Lady: The Story of Dr. Zanganeh

This partnership resulted in Imbruvica, a revolutionary drug for chronic lymphocytic leukemia. Its success led to the acquisition of Pharmacyclics by AbbVie in 2015 for $21 billion. Zanganeh, who had invested $1 million in the company, earned $225 million from the deal, securing her place among biotech’s elite.